FDA 483 - Dr Reddy's Laboratories Limited - June 16, 2017

During an FDA inspection conducted from June 12-16, 2017, Dr. Reddy's Laboratories Limited, located in Pradesh, India, received a Form FDA 483 outlining significant observations related to their laboratory systems. The primary issue identified was that the testing and release of drug products for distribution did not consistently ensure satisfactory conformance to final specifications. Specifically, the inspection noted deficiencies in laboratory practices for several drug products. For exhibit batches of a particular powder, manual integration was used for related substance testing, raising concerns about data integrity and accuracy. Furthermore, different processing methods were inconsistently applied to system suitability solutions, standards, and samples during both release and stability testing for various powder and tablet products. This inconsistency was observed across initial release, long-term, and accelerated stability samples. These observations indicate a failure to adhere to appropriate laboratory controls and quality standards, which are essential for ensuring drug product safety and efficacy. Dr. Reddy's Laboratories Limited is required to address these findings by implementing comprehensive corrective actions to ensure all testing and release procedures consistently meet regulatory expectations and product specifications. This includes reviewing and standardizing laboratory processing methods and ensuring robust data integrity practices are maintained.